- Thorvaldsdottir, Birna
- Mansouri, Larry
- Sutton, Lesley-Ann
- Nadeu, Ferran
- Meggendorfer, Manja
- Parker, Helen
- Brieghel, Christian
- Laidou, Stamatia
- Moia, Riccardo
- Rossi, Davide
- Kotaskova, Jana
- Delgado, Julio
- Rodríguez-Vicente, Ana Eugenia
- Benito, Rocío
- Rigolin, Gian Matteo
- Bonfiglio, Silvia
- Scarfò, Lydia
- Mattsson, Mattias
- Davis, Zadie
- Baliakas, Panagiotis
- Rapado, Inmaculada
- Mirás, Fátima
- Martínez-López, Joaquín
- Serna, Javier de la
- Hernández, Jesús M.
- Larráyoz, María José
- Calasanz, Mª Jose
- Smedby, Karin E.
- Espinet, Blanca
- Puiggros, Anna
- Bullinger, Lars
- Bosch, Francesc
- Tazón‐Vega, Bárbara
- Baran-Marszak, Fanny
- Oscier, David
- Nguyen-Khac, Florence
- Zenz, Thorsten
- Terol, María José
- Cuneo, Antonio
- Hernández-Sánchez, María
- Pospisilova, Sarka
- Gaidano, Gianluca
- Niemann, Carsten U.
- Campo, Elías
- Strefford, Jonathan C.
- Ghia, Paolo
- Stamatopoulos, Kostas
- Rosenquist, Richard
Despite the well-established adverse impact of del(11q) in chronic lymphocytic leukemia (CLL), the prognostic significance of somatic ATM mutations remains uncertain. We evaluated the effects of ATM aberrations (del(11q) and/or ATM mutations) on time-to-first-treatment (TTFT) in 3631 untreated patients with CLL, in the context of IGHV gene mutational status and mutations in nine CLL-related genes. ATM mutations were present in 246 cases (6.8%), frequently co-occurring with del(11q) (112/246 cases, 45.5%). ATM-mutated patients displayed a different spectrum of genetic abnormalities when comparing IGHV-mutated (M-CLL) and unmutated (U-CLL) cases: M-CLL was enriched for SF3B1 and NFKBIE mutations, whereas U-CLL showed mutual exclusivity with trisomy 12 and TP53 mutations. Isolated ATM mutations were rare, affecting 1.2% of Binet A patients and <1% of M-CLL cases. While univariable analysis revealed shorter TTFT for Binet A patients with any ATM aberration compared to ATM-wildtype, multivariable analysis identified only del(11q), trisomy 12, SF3B1, and EGR2 mutations as independent prognosticators of shorter TTFT among Binet A patients and within M-CLL and U-CLL subgroups. These findings highlight del(11q), and not ATM mutations, as a key biomarker of increased risk of early progression and need for therapy, particularly in otherwise indolent M-CLL, providing insights into risk-stratification and therapeutic decision-making., This work was in part supported by; Associazione Italiana per la Ricerca sul Cancro—AIRC, Milano, Italy (Investigator Grant #27566, P.I. Ghia Paolo) and Special Program on Metastatic Disease— 5 per mille #21198 program—P.I. Foà Roberto, G.L. Paolo Ghia, Gianluca Gaidano); ; “la Caixa” Foundation (Health Research 2017 Program HR17-00221); the American Association for Cancer Research (2021 AACR-Amgen Fellowship in Clinical/Translational Cancer Research, 21-40-11-NADE), the European Hematology Association (EHA Junior Research Grant 2021, RG-202012-00245), and the Lady Tata Memorial Trust (International Award for Research in Leukemia 2021- 2022, LADY_TATA_21_3223); the Hellenic Precision Medicine Network in Oncology; project ODYSSEAS (Intelligent and Automated Systems for enabling the Design, Simulation and Development of Integrated Processes and Products) implemented under the “Action for the Strategic Development on the Research and Technological Sector”, funded by the Operational Program “Competitiveness, Entrepreneurship and Innovation” (NSRF 2014-2020) and co-financed by Greece and the European Union, with grant agreement no: MIS 5002462”; MHCZ—DRO (FNBr, 65269705), NV21-08-00237 and the project National Institute for Cancer Research (Program EXCELES, ID Project No. LX22NPO5102)—Funded by the European Union—Next- Generation EU; Instituto de Salud Carlos III (ISCIII), “PI21/00983”, co-funded by the European Union; Instituto de Salud Carlos III (ISCIII), “PI21/00983”, co- funded by the European Union; Fondo di Ateneo per la Ricerca (FAR) 2019, 2020 and 2021 of the University of Ferrara (GMR; AC), Associazione Italiana contro le Leucemie- Linfomi e Mieloma ONLUS Ferrara (AC; GMR), BEAT Leukemia Foundation Milan Italy (AC); the Danish Cancer Society and the CLL-CLUE project under the frame of ERA PerMed; Cancer Research UK (ECRIN-M3 accelerator award C42023/A29370, Southampton Experimental Cancer Medicine Center grant C24563/A15581, Cancer Research UK Southampton Center grant C34999/A18087, and program C2750/ A23669); the Swedish Cancer Society (22 2448 Pj), the Swedish Research Council (2020-01750), Region Stockholm (ALF/FoUI-962423), and Radiumhemmets Forskningsfonder (194133), Stockholm; CGI-Clinics, a European Union’s Horizon 2022-2027 program under grant agreement 101057509., Peer reviewed